ClinConnect ClinConnect Logo
Search / Trial NCT05329402

Disposable Powered Articulating Linear Cutter Stapler in Total-Thoracoscopic Anatomic Lobectomy (Segmentectomy)

Launched by FENGH MEDICAL CO., LTD. · Apr 8, 2022

Trial Information

Current as of August 21, 2025

Completed

Keywords

ClinConnect Summary

By comparing the effectiveness and safety of the disposable electric-endoscopic linear cutter stapler and cartridge (the subject product) produced by Jiangsu Fengh Medical Co., Ltd. and the similar product (electric-endoscopic linear cutter stapler with articulating head) produced by Johnson \& Johnson in total-thoracoscopic anatomic lobectomy (segmentectomy), to prove that the subject product can be used for pulmonary tissue resection and anastomosis, and that the clinical trial meets the requirements of Good Clinical Practice for Medical Devices, Guidelines for Clinical Trial Design of Me...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Subjects aged 18-70 (inclusive), with no gender limitation;
  • 2. The subject plans to undergo thoracoscopic anatomic pulmonary lobectomy (pulmonary segment);
  • 3. Subjects or their guardians can understand the purpose of the study, show sufficient compliance with the study protocol, and sign the informed consent.
  • Exclusion Criteria:
  • 1. Subjects have contraindications of video-assisted thoracoscopy;
  • 2. The preoperative imaging results of the subjects indicated the presence of severe pleural adhesion and significant calcified hilar lymph nodes;
  • 3. Subjects' platelet (PLT) \<60x 10%/L or INR \> 1.5;
  • 4. Subjects forced expiratory volume in 1 second (FEV1)/expected value ≤50%, or forced expiratory volume in 1 second (FEV1)/use Vital capacity (FVC)≤60%;
  • 5. Cardiac ejection fraction ≤50%;
  • 6. Major organ failure or other serious diseases (including clinically relevant cardiovascular diseases or within 12 months prior to enrollment) Myocardial infarction; A history of severe neurological or psychiatric illness; The presence of a serious infection before surgery that must be controlled with medication; Dissemination of activity Sexual intravascular coagulation; At high risk of blood clots);
  • 7. The subject is a pregnant or lactating woman;
  • 8. The subject participated in clinical trials of other drugs or devices within 1 month prior to the trial;
  • 9. Other conditions that the researcher judged inappropriate for inclusion. .

About Fengh Medical Co., Ltd.

Fengh Medical Co., Ltd. is a leading clinical trial sponsor specializing in the development and commercialization of innovative medical technologies and therapeutics. Committed to advancing healthcare solutions, the company focuses on rigorous research methodologies and adherence to regulatory standards to ensure the safety and efficacy of its products. With a multidisciplinary team of experts, Fengh Medical is dedicated to fostering partnerships with healthcare professionals and institutions to drive clinical excellence and improve patient outcomes. Through its strategic initiatives, the company aims to contribute significantly to the global medical landscape and enhance the quality of life for patients worldwide.

Locations

Jiangyin, Jiangsu, China

Patients applied

0 patients applied

Trial Officials

Yusheng Shu

Principal Investigator

Northern Jiangsu People's Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials